Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: Comparison with atenolol

被引:275
作者
London, GM
Asmar, RG
O'Rourke, MF
Safar, ME
机构
[1] Hop Hotel Dieu, Ctr Diagnost, F-75004 Paris, France
[2] Hop Manhes, Fleury Merogis, France
[3] Inst Cardiovasc, Paris, France
[4] St Vincent Hosp, Darlinghurst, NSW, Australia
关键词
D O I
10.1016/j.jacc.2003.07.039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The goal of this study was to determine if a low-dose combination of the angiotensin-converting enzyme inhibitor perindopril (Per) and the diuretic indapamide (Ind) reduces central (thoracic aorta, carotid artery) as well as brachial systolic blood pressure (SBP) more than the beta-blocker atenolol and to determine the hemodynamic factors influencing independently brachial and central SBP: pulse wave velocity (PWV) and pattern of wave reflections. Background In high cardiovascular risk populations, angiotensin blockade improves survival without affecting brachial SBP and diastolic blood pressure (DBP). Whether central SBP, which is physiologically lower than brachial SBP, is significantly reduced has never been investigated. Methods This study was a double-blind randomized trial for one year in patients with essential hypertension. Results For a similar DBP reduction, Per/Ind decreased SBP significantly more than atenolol, with a more pronounced reduction for central than for brachial SBP. After one year, the difference between brachial and central SBP was maintained by Per/Ind (8.28+/-1.53 mm Hg) and significantly attenuated by atenolol (0.29+/-1.61 min Hg). Under atenolol, the principal factor modulating SBP reduction was mean blood pressure. Under Per/Ind, this parameter played a minor role, and the central SBP reduction implied a major role for disturbed PWV and wave reflections. Conclusions Under Per/Ind, but not atenolol, normalization of brachial SBP is achieved with a significantly greater reduction of central SBP. This hemodynamic profile reflects changes of wave reflections issued from distal arterial and arteriolar territory, where Per/Ind, but not atenolol, is known to improve vessel wall structure.
引用
收藏
页码:92 / 99
页数:8
相关论文
共 21 条
[1]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[2]   Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient - A comparison with atenolol [J].
Asmar, RG ;
London, GM ;
O'Rourke, ME ;
Safar, ME .
HYPERTENSION, 2001, 38 (04) :922-926
[3]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[4]   DIFFERENT EFFECTS OF FOSINOPRIL AND ATENOLOL ON WAVE REFLECTIONS IN HYPERTENSIVE PATIENTS [J].
CHEN, CH ;
TING, CT ;
LIN, SJ ;
HSU, TL ;
YIN, FCP ;
SIU, CO ;
CHOU, P ;
WANG, SP ;
CHANG, MS .
HYPERTENSION, 1995, 25 (05) :1034-1041
[5]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[6]   Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients [J].
Girerd, X ;
Giannattasio, C ;
Moulin, C ;
Safar, M ;
Mancia, G ;
Laurent, S .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (05) :1064-1073
[7]  
Guerin AP, 2001, CIRCULATION, V103, P987
[8]   Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats - Effects of angiotensin receptor antagonism and converting enzyme inhibition [J].
Intengan, HD ;
Thibault, G ;
Li, JS ;
Schiffrin, EL .
CIRCULATION, 1999, 100 (22) :2267-2275
[9]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860
[10]  
Nichols W W, 2001, J Cardiovasc Pharmacol Ther, V6, P5, DOI 10.1177/107424840100600102